医学
内科学
骨保护素
内分泌学
兰克尔
类风湿性关节炎
N-末端末端肽
乙膦酸
骨矿物
骨质疏松症
破骨细胞
维生素K2
骨吸收
碱性磷酸酶
骨钙素
维生素
受体
激活剂(遗传学)
化学
酶
生物化学
作者
Minoru Morishita,Masakazu Nagashima,K. Wauke,Hiroshi Takahashi,Kazuya Takenouchi
出处
期刊:PubMed
日期:2008-03-01
卷期号:35 (3): 407-13
被引量:3
摘要
To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA).Subjects comprised 79 patients with RA who were receiving prednisolone, divided into 3 groups: Group K, Vit K2 alone; Group KE, Vit K2 plus etidronate; and Group KR, Vit K2 plus risedronate. During a 24-month treatment and followup period, levels of N-terminal telopeptide of type I collagen (NTx) and bone alkaline phosphatase were measured. Bone mineral density (BMD) of the 3 groups was measured using dual-energy x-ray absorptiometry. Damage score to fingers on radiographic findings were measured according to the Larsen method. Serum levels of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) were measured.Falls in rate of change of BMD decreased after 18 months in groups KR and KE. Larsen damage scores indicated a significant difference between Group KE and other groups. Significant decreases in serum NTx were observed in groups KE and KR at all timepoints, but not in Group K. Levels of RANKL decreased significantly in all 3 groups.Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL.
科研通智能强力驱动
Strongly Powered by AbleSci AI